Publié le Laisser un commentaire

Announcing Vitalist Bay, a Pop-Up City in the Bay Area

A unique project is set to go live next spring in the Bay Area. Organized by the Vitalism Foundation, it promises to be one of the largest longevity-related events ever.

They’re popping up!

Since the pop-up city of Zuzalu took the longevity community by storm in early 2023, its innovative concept has inspired a wave of adaptations around the globe. These include Vitalia on the island of Roatan, Honduras; ZuVillage in Georgia (the country, not the state); and Zelar City in Berlin, each offering its own spin on the original formula.

A pop-up city gathers like-minded people, blending co-living with a packed schedule of activities such as conferences, workshops, and hackathons. When the project is longevity-focused, the daily routine revolves around health and wellness, including healthy meals, cold plunges, yoga classes, detailed blood tests, and on-site treatments.

Pop-up cities give participants an inspiring glimpse into a future where people aren’t bound by national borders but instead unite around shared values and interests. This ambitious concept, known as “network states,” was coined by entrepreneur Balaji Srinivasan. Some projects, like Vitalia, have already taken the next step by establishing a continuous presence with a small, permanent community rather than disbanding after a few months.

Betting big on the Bay Area

Most pop-up cities have been set in remote or underdeveloped locations, due to factors like lower costs and relaxed regulations. Building such a project in a bustling, expensive metropolis is a serious challenge – one that Vitalist Bay is stepping up to meet.

Vitalist Bay, a future pop-up city set to operate in Berkeley, California, during April and May of 2025, is being organized by the Vitalism Foundation, a major non-profit in the longevity space. In a press release, the organizers described the initiative as “humanity’s boldest effort to extend healthy lifespan and solve aging” and “the Bay Area’s first longevity zone.”

Like a proper longevity-oriented pop-up city should, Vitalist Bay will offer its inhabitants and visitors perks like a gym, a sauna, a large co-working space, advanced diagnostics such as DEXA scans and VO2max tests, and, generally, a “pro-health social environment.” ‘Bayers’ will also be able to participate in a community clinical trial.

The program

Vitalist Bay boasts an exceptionally comprehensive program covering a variety of interconnected topics, including longevity science, decentralized science and network states, biostasis and cryopreservation, AI in biology, and investment in longevity biotech. Notably, an entire week will focus on healthcare policy, philosophy, and ethics – an encouraging sign of growing interest in longevity advocacy, a vital part of the movement.

“Aging and longevity have such wide scope – from policy and regulations to science and technology, investing in startups, and even crypto with decentralized science. Unfortunately, the interaction between these different areas has been quite limited,” Adam Gries, Vitalism’s co-founder, said to Lifespan.io. “Vitalist Bay is longevity’s new capital, which is a triple entendre – human capital, financial capital, and physical capital – because we feel longevity has been missing a focal point that converges its different aspects.”

The locals and the visitors

Despite the Bay Area’s notoriously high cost of living, Vitalist Bay will offer reasonably priced accommodations for several dozen permanent residents. “The event will be centered around the Lighthaven campus, where the rationalist community is based,” said Nathan Chen, co-founder of Vitalism and the Longevity Biotech Fellowship. “We’ll bring in hundreds, if not thousands, of longevity experts across different domains with the common focus of solving the problem of aging.”

The primary emphasis, however, will be on visitors. “Vitalia and Zuzalu were designed as pop-up cities with residents as the dominant group,” Adam noted. “Our longevity zone is different – the dominant group will be visitors coming for shorter periods. With a venue that can host a thousand people but only 70 residents, we’re expecting thousands of attendees to participate in our conferences.”

Elaborating on why Vitalist Bay differs from its predecessors, Adam added, “Being in the Bay Area is crucial. Long-term pop-up cities in remote locations with limited infrastructure, research ecosystems, or innovation history are inherently restrictive. Think about the 10,000 or more angel investors in the Bay Area; how many would travel to Vitalia? Maybe the hardcore enthusiasts, but not those who are merely curious or geographically tied. With a local event, we can spark engagement beyond the dedicated longevity community.”

What’s next?

“Among the outputs we’re aiming for,” Nathan said, “are policy and ethics statements from philosopher groups, think tanks with recommendations for research funding priorities, and local community partnerships that emphasize the pro-social aspects of longevity. We also want to engage with the local art scene and, more broadly, build projects that bridge different parts of the longevity ecosystem. Of course, we’ll try to get more capital into companies and initiatives, both for-profit and nonprofit.”

Another ambitious goal is to create a longer-term physical presence in the Bay Area. “For that,” Nathan explained, “we’re partnering with Berlin House, which owns a 16-story tower in San Francisco. We’ll be governing one floor dedicated to longevity in partnership with VitaDAO and Foresight Institute. This could become our longer-term venue after the two-month event.”

We would like to ask you a small favor. We are a non-profit foundation, and unlike some other organizations, we have no shareholders and no products to sell you. All our news and educational content is free for everyone to read, but it does mean that we rely on the help of people like you. Every contribution, no matter if it’s big or small, supports independent journalism and sustains our future.
Publié le Laisser un commentaire

BioAge Labs Ends STRIDES Phase 2 Clinical Trial

RICHMOND, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) — BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company has made the decision to discontinue the ongoing STRIDES Phase 2 study of its investigational drug candidate azelaprag as monotherapy and in combination with tirzepatide after liver transaminitis without clinically significant symptoms was observed in some subjects receiving azelaprag. No transaminase elevations were observed in the tirzepatide only treatment group.

“Patient safety is our top priority in the conduct of our clinical studies,” said Kristen Fortney, PhD, CEO and co-founder of BioAge. “We made the difficult decision to discontinue the STRIDES Phase 2 study of azelaprag because it became clear that the emerging safety profile of the current doses tested is not consistent with our goal of a best-in-class oral obesity therapy. While this outcome is a significant disappointment, we remain encouraged by azelaprag’s promising preclinical and Ph1b efficacy profile. We remain committed to our focus on developing therapies for metabolic aging. In parallel to assessing the next steps for the azelaprag program, we will continue to advance our NLRP3 inhibitor program as well as additional research programs with novel mechanisms emerging from our platform.”

STRIDES is a randomized, double-blind, placebo-controlled Phase 2 clinical trial of azelaprag as monotherapy and in combination with tirzepatide that planned to enroll approximately 220 individuals with obesity aged 55 years and older (link). The trial was designed to evaluate the efficacy as measured by body weight reduction and other outcomes, safety, and tolerability of two oral doses of azelaprag (300 mg, once or twice daily) in combination with tirzepatide (5 mg subcutaneous injection once weekly). An azelaprag monotherapy arm was included to provide additional safety information.

Of 204 subjects enrolled in STRIDES as of today, 11 subjects in the azelaprag treatment groups were observed to have transaminase elevations with no clinically significant symptoms. Dosing of all subjects will be discontinued, and no additional subjects will be enrolled. Clinical follow-up of enrolled subjects will continue off drug. The Company intends to further analyze available STRIDES clinical data from all enrolled subjects. The Company has notified all study investigators and regulatory authorities including the U.S. Food and Drug Administration (FDA) of the Company’s decision to discontinue enrollment.   The Company intends to share updated plans for azelaprag in Q1 2025.

BioAge continues to advance its pipeline of therapeutic candidates targeting the biology of aging to treat metabolic diseases. The Company’s novel class of brain-penetrant NLRP3 inhibitors, which have demonstrated high potency and a novel binding site, are progressing toward IND submission, anticipated in the second half of 2025. The NLRP3 inhibitor program targets neuroinflammation, which is linked to both metabolic and neurodegenerative diseases. In addition, BioAge is advancing multiple targets derived from its proprietary discovery platform, which analyzes molecular data spanning over 50 years of human aging trajectories.

About BioAge Labs, Inc.
BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. BioAge’s lead product candidate, azelaprag, is an orally available small molecule agonist of APJ that was observed to promote metabolism and prevent muscle atrophy on bed rest in a Phase 1b clinical trial. BioAge is also developing orally available small molecule brain penetrant NLRP3 inhibitors for the treatment of diseases driven by neuroinflammation. BioAge’s preclinical programs, based on novel insights from the company’s discovery platform built on human longevity data, address key pathways in metabolic aging.

Forward-looking statements
This press release contains “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding our plans to develop and commercialize our product candidates, our business strategy, results of our ongoing or planned clinical trials, the timing of any future updates to our programs and the clinical utility of our product candidates. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “might,” “plan,” “potential,” “possible,” “will,” “would,” and other words and terms of similar meaning. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including: our ability to develop, obtain regulatory approval for and commercialize our product candidates; the timing and results of preclinical studies and clinical trials; the risk that positive results in a preclinical study or clinical trial may not be replicated in subsequent trials or success in early stage clinical trials may not be predictive of results in later stage clinical trials; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events; failure to protect and enforce our intellectual property, and other proprietary rights; failure to successfully execute or realize the anticipated benefits of our strategic and growth initiatives; risks relating to technology failures or breaches; our dependence on collaborators and other third parties for the development of product candidates and other aspects of our business, which are outside of our full control; risks associated with current and potential delays, work stoppages, or supply chain disruptions; risks associated with current and potential future healthcare reforms; risks relating to attracting and retaining key personnel; failure to comply with legal and regulatory requirements; risks relating to access to capital and credit markets; and the other risks and uncertainties that are detailed under the heading “Risk Factors” included in BioAge’s Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC) on November 7, 2024, and other filings with the SEC filed from time to time. BioAge undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Contacts
PR: Chris Patil, media@bioagelabs.com
IR: Elena Liapounova, ir@bioagelabs.com
Partnering: partnering@bioagelabs.com
Web: https://bioagelabs.com

Publié le Laisser un commentaire

Longevity Market Recap – November 2024

As we head toward the festive season, ‘sharing is caring’ really is the motto in the longevity world. Collaborations between companies, foundations, and funders are seeing early results.

From AI discoveries to potential policy changes that allow wider medicine access, November has been a month of growth. Of course, not all ambitious adventures succeed, but transformative change in longevity tech is making strides.

Upcoming conferences and events

2nd Roundtable of Longevity Clinics is underway

On December 6-7 2024, the International Institute of Longevity will host the 2nd Roundtable of Longevity Clinics. This event brings together leading longevity practitioners, businesses, and investors in one space to delve into epigenetic clocks, regenerative medicine, clinical interventions, and lifestyle practices such as nutrition and exercise, with a focus on enhancing human healthspan and lifespan. Find out more about the event here.

Founders Longevity Forum in Singapore is set for February

The Founders Longevity Forum will gather experts in epigenetics, AI, and regenerative medicine from around the world. The recently released agenda includes precision geromedicine and longevity investment as topics of interest, focusing on healthspan extension and aging solutions. Speakers include Hannah Went and Petr Sramek. Tickets to the event are available here.

Tech breakthroughs & new research

Genesis Therapeutics partners with NVIDIA to accelerate AI drug discovery

AI-focused drug discovery company Genesis Therapeutics has announced a partnership with NVIDIA to optimize its neural networks and enhance its process for finding 3D protein and molecule data. This partnership focuses on refining neural networks and using generative and predictive Ai to target proteins and design therapies.

Telomir Pharma moving ahead to Phase 2 after successful clinical trial

Telomere-focused biotech company Telomir Pharmaceuticals has announced its plans to proceed to Phase 2 clinical trials with its compound Telomir-1. In recent C. elegans studies, the drug has provided improvements in lifespan, healthspan, and mobility, making it a leading candidate for future testing.

Virtual reality tech aids in early cognitive decline detection

Virtuleap, a VR company that combines neuroscience with technology, has created a tool alongside pharmaceutical companies to enhance early detection of dementia. The current kit, known as Cogniclear VR analyses real-world tasks and physiological cues like pupil dilation and heart rate variability to gather 250K+ data points in just under 3 minutes. This new system could offer clinicians a new way to analyze cognitive health and aid in early interventions.

DeSci and DAOs

VitaDAO has partnered with Pump Science to test longevity compounds

VitaFAST, backed by VitaDAO, has teamed up with Pump Science to utilize gamification to test new longevity compounds. The project seeks to evaluate compounds over 12 weeks in worm life extension experiments. During this initial stage, any promising compounds will progress to further testing, being incorporated into VitaFAST’s research and products.

Crypto platform backs BIO Protocol to boost science funding

Binance Labs has announced its backing of BIO Protocol, a decentralized science platform that utilizes blockchain to fund biotech DAOs working in research for longevity, rare disease and other areas. Dubbed the “Y Combinator”, a start-up accelerator, of science, BIO has raised $13 million to date and has plans to keep expanding.

News and funding

$84M secured by TRex Bio to advance immune-regulating therapy

San Francisco-based biotech TRex Bio has just raised $84 million in Series B funding to support its Phase 1 trial of TRB-061, a TNFR2 agonist targeting regulatory T cells (Tregs). This is hoped to control inflammation and promote healing. Led by Delos Capital, the funding will also support plans to expand the company’s clinical pipelines for wider therapies into inflammatory and autoimmune diseases.

Metabolic tracking on your finger: coming soon

Dexcom and Oura have partnered to reinvigorate the health wearables market with innovative ring technology that allows users to monitor their blood glucose level from a ring. Dexcom is a leader in the glucose monitoring sphere, whole Oura is known for its health wearables that track metrics such as sleep, stress, health and more. This latest collaboration has seen Dexcom invest $75 million into Oura with plans for a launch in mid 2025.

Potential Medicare expansion could offer obesity drugs to more people

Weight loss drugs, such as Wegovy, Mounjaro, Saxenda, and Ozempic, have hit headlines recently. As these drugs are currently available in both the US and UK as treatments for diabetes, Medicare in the US is contemplating offering increased access to these preparations to a wider range of the population. The latest discussion suggests that offering these medications to obese patients could cut out-of-pocket expenses by 95% and reduce diabetes risk more broadly. Changes to these regulations could be set to appear as early as 2026.

AI doctor’s office shuts

Not all innovations end with success, but they are always learning experiences. An AI health start-up, which last year raised $500 million to create the world’s first AI doctor’s office, known as a CarePod, has ceased its operations. As the team at Forward helps its patients look for new providers, new lessons are learned for the future of AI in healthcare.

Social media pages to follow this month

BIO Protocol — DeSci accelerator

Paul Kohlhaas — Pioneer in the world of DeSci

Quantum Bio DAO — Supports community building, governance tokens, and open competition for research grants